ATS GUIDELINES Bundle

3 Diagnosis ➤ For patients with newly identified ILD whose differential diagnosis includes nonfibrotic HP or fibrotic HP, the guideline committee makes no recommendation or suggestion for or against the use of a specific questionnaire to identify potential inciting agents of HP. Instead, the guideline committee recommends the development and validation of a questionnaire. ➤ For patients with newly identified ILD whose differential diagnosis includes nonfibrotic HP, the guideline committee suggests performing serum IgG testing that targets potential antigens associated with HP (suggestion, very low confidence in the estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests performing serum IgG testing that targets potential antigens associated with HP (suggestion, very low confidence in the estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes nonfibrotic HP, the guideline committee recommends BAL with lymphocyte cellular analysis (recommendation, very low confidence in the estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests BAL with lymphocyte cellular analysis (suggestion, very low confidence in the estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes nonfibrotic HP, the guideline committee suggests TBBx (suggestion, very low confidence in the estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee makes no recommendation or suggestion for or against TBBx. ➤ For patients with newly identified ILD whose differential diagnosis includes nonfibrotic HP, the guideline committee makes no recommendation or suggestion for or against TBLC. ➤ For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests TBLC (suggestion, very low confidence in estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes nonfibrotic HP, the guideline committee suggests SLB. This recommendation is intended for after alternative diagnostic options have been exhausted (suggestion, very low confidence in estimated effects). ➤ For patients with newly identified ILD whose differential diagnosis includes fibrotic HP, the guideline committee suggests SLB. This recommendation is intended for after alternative diagnostic options have been exhausted (suggestion, very low confidence in estimated effects).

• Cover